Processa acquires Vidya Therapeutics with $200 million placement

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) said on July 29, 2026 that it had acquired Vidya Therapeutics, Inc., a clinical-stage biotechnology company developing the BTK inhibitor VT-7208, according to a release. The acquisition came with a definitive agreement for a concurrent private placement expected to raise approximately $200 million in gross proceeds, before placement agent and other offering expenses. The company said its cash at closing, including the expected placement proceeds, is expected to fund operations into the second half of 2029.

The transaction terms

The acquisition is a stock-for-stock transaction in which all outstanding equity interests of Vidya will be exchanged at a fixed ratio for 558,398 shares of Processa common stock and 142,744.100 shares of Series A non-voting convertible preferred stock. Processa's board approved the acquisition, as did Vidya's board and stockholders. The closings of the acquisition and the private placement are not subject to Processa stockholder approval, but stockholder approval is required before the Series A preferred can convert into common stock.

Investors in the private placement will receive 163,774.679 shares of Series A preferred stock at $1,221.19 per share, or $1.22119 per share on an as-converted basis. The placement is expected to close on July 30, 2026. Each Series A share will automatically convert into 1,000 shares of common stock, subject to Processa stockholder approval under Nasdaq listing rules and to beneficial ownership limits set by each holder. The company described the offering as oversubscribed.

Advisers and investors

Named investors include Bain Capital Life Sciences, Janus Henderson Investors, RA Capital Management, SilverArc Capital, ADAR1 Capital Management, Cormorant Asset Management, Integral Health Asset Management, Marshall Wace, Octagon Capital and Soleus Capital. The release puts former Vidya equity holders at about 46.0% and placement investors at about 52.6%, on a fully diluted basis.

Leerink Partners is exclusive financial advisor to Vidya and lead placement agent for the private placement. Evercore ISI, UBS Investment Bank and Wells Fargo Securities are co-placement agents. Tungsten Advisors is financial advisor to Processa and provided a fairness opinion to Processa's board. Cooley LLP is legal counsel to Vidya, Katten Muchin Rosenman LLP is legal counsel to Processa, and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. is legal counsel to the placement agents.

Pipeline and financial position

Processa expects to start Phase 2 studies of VT-7208 in food allergy and chronic spontaneous urticaria in the second half of 2026, and in relapsing multiple sclerosis in the first half of 2027. Data from the food allergy study are expected in the second half of 2027, data from the CSU study in the first half of 2028 and data from the RMS study in the second half of 2028. In a Phase 1 trial, low milligram doses taken once daily produced robust and sustained target engagement, and no serious adverse events were observed.

George Ng, Processa's Chief Executive Officer, said: "This transaction with Vidya represents a compelling opportunity to create meaningful value for our shareholders." Its annual report for 2025 reported a net loss of $13.6 million, compared with $11.9 million for 2024, and cash from operations of negative $11.4 million, compared with negative $11.2 million.

What the deal costs and what is unproven

For existing Processa holders the price is dilution. The release puts them at about 0.9% of the common stock on a fully diluted basis after the deal, and the conversion of the preferred stock still needs their approval under Nasdaq rules. The company lost $13.6 million in 2025, so the roughly $200 million is expected money, not cash in hand, until the placement closes.

The release reports a Phase 1 trial with no serious adverse events and "robust and sustained" target engagement, but gives no patient numbers, no efficacy data and no comparison with other BTK inhibitors. The release says Vidya believes the design may reduce liver toxicity risk relative to earlier drugs. That is a belief, not a result. The first Phase 2 data are not expected until the second half of 2027.

Report an error

Companies in this story

PCSAProcessa Pharmaceuticals, Inc.NASDAQ · United StatesOpen the starter desk